260 related articles for article (PubMed ID: 24996116)
1. Earlier presentation and application of curative treatments in hepatocellular carcinoma.
Ulahannan SV; Duffy AG; McNeel TS; Kish JK; Dickie LA; Rahma OE; McGlynn KA; Greten TF; Altekruse SF
Hepatology; 2014 Nov; 60(5):1637-44. PubMed ID: 24996116
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
3. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.
El-Serag HB; Siegel AB; Davila JA; Shaib YH; Cayton-Woody M; McBride R; McGlynn KA
J Hepatol; 2006 Jan; 44(1):158-66. PubMed ID: 16290309
[TBL] [Abstract][Full Text] [Related]
4. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States.
Davila JA; Duan Z; McGlynn KA; El-Serag HB
J Clin Gastroenterol; 2012 Jan; 46(1):71-7. PubMed ID: 22157221
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
[TBL] [Abstract][Full Text] [Related]
6. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
8. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
10. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
Pecorelli A; Lenzi B; Gramenzi A; Garuti F; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Felder M; Morisco F; Gasbarrini A; Baroni GS; Foschi FG; Biasini E; Masotto A; Virdone R; Bernardi M; Trevisani F;
Liver Int; 2017 Mar; 37(3):423-433. PubMed ID: 27566596
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
[No Abstract] [Full Text] [Related]
12. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Waziry R; Gomaa A; Waked I; Dore GJ
Arab J Gastroenterol; 2018 Mar; 19(1):26-32. PubMed ID: 29506913
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
Ohki T; Kondo M; Karasawa Y; Kawamura S; Maeshima S; Kojima K; Seki M; Toda N; Shioda Y; Tagawa K
Adv Ther; 2017 May; 34(5):1097-1108. PubMed ID: 28389996
[TBL] [Abstract][Full Text] [Related]
14. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
Meng XC; Chen BH; Huang JJ; Huang WS; Cai MY; Zhou JW; Guo YJ; Zhu KS
World J Gastroenterol; 2018 Jan; 24(4):484-493. PubMed ID: 29398869
[TBL] [Abstract][Full Text] [Related]
15. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
Geschwind JF; Kudo M; Marrero JA; Venook AP; Chen XP; Bronowicki JP; Dagher L; Furuse J; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Ye SL; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
Radiology; 2016 May; 279(2):630-40. PubMed ID: 26744927
[TBL] [Abstract][Full Text] [Related]
16. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.
Zhang X; El-Serag HB; Thrift AP
Cancer Causes Control; 2021 Apr; 32(4):317-325. PubMed ID: 33394207
[TBL] [Abstract][Full Text] [Related]
17. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
Zhong BY; Ni CF; Chen L; Zhu HD; Teng GJ
Radiology; 2017 Aug; 284(2):583-592. PubMed ID: 28263701
[TBL] [Abstract][Full Text] [Related]
18. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
[TBL] [Abstract][Full Text] [Related]
19. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
[TBL] [Abstract][Full Text] [Related]
20. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
Kudo M; Lencioni R; Marrero JA; Venook AP; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Lehr R; Heldner S; Ye SL
Liver Int; 2016 Aug; 36(8):1196-205. PubMed ID: 26901163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
